Aimei Health Technology Co., Ltd. AFJK

12.19 0.01 0.08% as of 25 Sep
Market cap
$38.6M
P/E
60.0×

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 47.79%

Capital & Financial Ratios

Market Cap 38.58
Revenue —
Net Income 0.41
Free Cash Flow (0.37)
Net Debt 2.19
Current Ratio 0.01
Debt/Equity (0.49)
P/E ratio 59.99
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next 5Y EPS Growth —
in millions of $

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1 0 0 0
Receivables — — — —
Inventory — — — —
Other — — — —
1 0 0 0
2023 2024 2025 Q'26
Payables — — — —
ST’ Debt — 0 2 2
Other — 0 1 1
0 1 3 4
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Revenue

Year
in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 (1)
’24 0 0 0 0 (1)
in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 (1)
’24 0 0 0 0 (1)
in millions of $ · fiscal quarters ending in the months shown

EPS

Mar Jun Sep Dec Year
’26 0.02 (0.03) — — —
’25 0.09 0.20 0.17 0.05 0.50
’24 0.36 0.29 0.35 0.21 1.20
fiscal quarters ending in the months shown

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — — — — 10.15 6.75

Analyst estimates 2026–2028

Powerpack
Low Price
— — — — — — — — 10.70 130.37
High Price
— — — — — — — 2 2 2
Employees
— — — — — — — 0 0 0
Revenue/Emp
— — — — — — — — — —
Revenue
— — — — — — — — — —
Gross Margin
— — — — — — — 0 3 1
EBT
— — — — — — — 0.00% 0.00% 0.00%
EBT Margin
— — — — — — — 0 3 1
Net Income
— — — — — — — — — —
Depreciation
— — — — — — — 0.00 0.00 0.00
Revenue/Sh
— — — — — — — 0.11 1.20 0.50
Earnings/Sh
— — — — — — — 0.00 (0.32) (0.27)
Cash Flow/Sh
— — — — — — — 0.00 0.00 0.00
Capex/Sh
— — — — — — — 0.00 (0.32) (0.27)
Free CF/Sh
— — — — — — — (0.09) (0.69) (1.91)
Book Value/Sh
— — — — — — — 2 2 2
Shares
— — — — — — — — — —
PE Ratio
— — — — — — — — — —
PS Ratio
— — — — — — — — — —
PB Ratio
— — — — — — — — — —
EV/Sales
— — — — — — — — — —
EV/FCF
— — — — — — — 0 (1) (1)
Op' Cash Flow
— — — — — — — — — —
Capex
— — — — — — — 0 (1) (1)
FCF
— — — — — — — 1 (1) (3)
Working Cap'
— — — — — — — — 0 2
Total Debt
— — — — — — — (1) 0 2
Net Debt
— — — — — — — 0 (1) (4)
Sh' Equity
— — — — — — — 0.00% 3.54% 2.47%
ROA
— — — — — — — 0.00% 0.00% 0.00%
ROIC
— — — — — — — 0.00% (316.91%) (38.29%)
ROE
predictions in italic, sparklines do not include predictions

All 10 years →

Aimei Health Technology Co., Ltd. (AFJK) key facts

  • Aimei Health Technology Co., Ltd. (AFJK) is a Shell Companies company in the Financial sector, listed on Nasdaq.
  • Net income was $1.1 million, or $0.50 per share (basic), a net margin of 0.00%.
  • As of September 25, 2026, AFJK traded at $12.19, a market capitalization of $38.6 million.
  • At that price the stock trades at 60.0× trailing-twelve-month earnings.
  • Return on equity was −38.3% and debt-to-equity -0.49.

Source: company filings (standardised) and stockrow calculations.

Aimei Health Technology Co., Ltd. (AFJK) Latest News

News by impact score

Fine-tune

8 Jul

4

Aimei Health Technology Co., Ltd. (AFJK) terminated its business combination agreement with United Hydrogen Group Inc. Failed merger deal alters AFJK's growth strategy and market positioning.

20 May

3

Aimei Health Technology Co., Ltd. (AFJK) received a NASDAQ notice regarding its delayed quarterly report. A NASDAQ delinquency notice for late filings raises compliance risks that can pressure short-term stock sentiment and trigger remediation steps.

21 Apr

4

Aimei Health Technology Co., Ltd. (AFJK) received a NASDAQ notice citing delay in filing its annual report. NASDAQ notice for delayed annual report signals compliance risks, potential delisting, and damaged investor confidence.

20 Jun

4

United Hydrogen Group Inc. and Aimei Health Technology Co., Ltd. have entered into a definitive business combination agreement for a merger, making United Hydrogen a publicly traded company on Nasdaq. The transaction values the combined company at an estimated enterprise value of approximately US$1.6 billion. The merger with United Hydrogen Group Inc. is a significant strategic move that is expected to fundamentally alter Aimei Health Technology Co., Ltd.'s competitive position and long-term prospects.

4

United Hydrogen Group Inc. and Aimei Health Technology Co., Ltd. have entered into a definitive business combination agreement for a merger. The transaction values the combined company at an estimated enterprise value of approximately US$1.6 billion. United Hydrogen is a comprehensive hydrogen solution provider, while Aimei Health Technology Co., Ltd. is a Cayman Islands special purpose acquisition company. The merger between United Hydrogen and Aimei Health Technology Co., Ltd. is expected to have a significant impact on the future and market performance of both companies, potentially altering their competitive positioning and long-term prospects.

stockrow.com/AFJK · For information only; not investment advice. · © 2026 stockrow.com